Delivery Order SPE2DB22D3004-SPE2DB25FSE60
- Not listed
- AmerisourceBergen Drug Corp was awarded a delivery order by the Defense Logistics Agency's Medical Supply Chain on September 9, 2025, for the supply of GAMUNEX-C 40 gram/400 milliliter vials. The contract is a firm fixed price delivery order with a ceiling value of $224,205.12 and an ultimate completion date of September 30, 2025. This award was competitively awarded with no set-aside designation. The place of performance is AmerisourceBergen's corporate headquarters in Conshohocken,...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $41,178.10 on July 24, 2025, for the supply of GAMUNEX-C 40 gram/400 milliliter vials. This competitively awarded, firm fixed-price contract carries an ultimate completion date of August 14, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order was issued without a set-aside designation, reflecting open competition among qualified...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 12, 2025, for GAMUNEX-C 20 gram/200 milliliter vials valued at $11,801.40 with firm fixed pricing. This is a non-set-aside delivery order with an ultimate completion date of September 3, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical federal medical procurement vendor, is executing this...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 29, 2025, for the supply of GAMUNEX-C 20 gram/200 milliliter vials valued at $11,801.40 with a firm fixed price. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The contract involves no set-aside designation and was competitively...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 3, 2025, for the supply of Gamunex-C 40 gram/400 milliliter vials with a ceiling value of $6,981.60 and an ultimate completion date of September 24, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and represents a child delivery order under AmerisourceBergen's broader pharmaceutical supply framework with DLA. The product will be delivered to...
- The Department of Defense Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on September 3, 2025, for the supply of GAMUNEX-C 40 gram/400 mL vials valued at $46,544.00, with completion scheduled for September 24, 2025. This firm fixed-price delivery order represents a non-competitive set-aside award and will be performed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. GAMUNEX-C is an immune globulin intravenous therapy used for treating...
- The Defense Logistics Agency awarded a $23,272 firm fixed-price delivery order to AmerisourceBergen Drug Corp on July 30, 2025, for the supply of GAMUNEX-C 40 gram/400 mL vials. This non-set-aside contract, which carries an ultimate completion date of August 20, 2025, is a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 and extending through December 2026. The product will be delivered to...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of GAMUNEX-C 20 gram/200 milliliter vials valued at $11,651.54 under a firm fixed-price contract with an ultimate completion date of August 18, 2025. This non-set-aside award represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 30, 2025, for the supply of GAMUNEX-C 40 Gram/400 mL vials, valued at $4,654.40 with a firm fixed price structure. This is an unset-aside, competitively awarded contract with an ultimate completion date of August 20, 2025, and performance at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. GAMUNEX-C is an intravenous immunoglobulin (IVIG) product used to treat primary...
- The U.S. Department of Defense, through its Medical Supply Chain division, awarded a delivery order to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of GAMUNEX-C 20 gram/200 milliliter vials valued at $56,646.72. This is a firm fixed-price, non-set-aside contract with a completion date of August 25, 2025, and will be performed at AmerisourceBergen's Conshohocken, Pennsylvania facility. GAMUNEX-C is an immune globulin intravenous (human) treatment used for immunodeficiency and...
- SPE2DB22D3004Indefinite Delivery Contract
- SPE2DB22D3004-SPE2DB25FSE60Delivery Order
AmerisourceBergen Drug Corp was awarded a delivery order contract by the Defense Logistics Agency (DLA) on August 27, 2025, for the supply of GAMUNEX-C 40 gram/400 milliliter vials, with a contract ceiling value of $2,327.20 and an ultimate completion date of September 18, 2025. This is a firm fixed-price delivery order with no set-aside designation, awarded through open competition. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The IDC serves as a global pharmaceutical support vehicle enabling AmerisourceBergen to supply a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs worldwide, including specialty medications, brand-name and generic drugs, and medical commodities across multiple therapeutic domains. GAMUNEX-C is an intravenous immunoglobulin (IVIG) therapy used to treat immunodeficiency disorders and other immune conditions, reflecting the critical nature of pharmaceutical supplies delivered under this contract vehicle to Defense Health Agency and other military healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.3k | 8/27/25 |